



Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Correction to: *Nature Communications*
<https://doi.org/10.1038/s41467-023-44195-x>,
published online 19 December 2023

<https://doi.org/10.1038/s41467-023-44575-3>

Published online: 03 January 2024



Nasser K. Altorki , Zachary H. Walsh, Johannes C. Melms , Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho , Paul J. Christos, Ashish Saxena, Olivier Elemento , Bhavneet Bhinder, Casey Ager, Amit Dipak Amin , Nicholas J. Sanfilippo, Vivek Mittal , Alain C. Borczuk , Silvia C. Formenti , Benjamin Izar & Timothy E. McGraw

In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024